GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guizhou Sanli Pharmaceutical Co Ltd (SHSE:603439) » Definitions » Change In Receivables

Guizhounli Pharmaceutical Co (SHSE:603439) Change In Receivables : ¥0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Guizhounli Pharmaceutical Co Change In Receivables?

Guizhounli Pharmaceutical Co's change in receivables for the quarter that ended in Jun. 2024 was ¥0 Mil. It means Guizhounli Pharmaceutical Co's Accounts Receivable stayed the same from Mar. 2024 to Jun. 2024 .

Guizhounli Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥-124 Mil. It means Guizhounli Pharmaceutical Co's Accounts Receivable increased by ¥124 Mil from Dec. 2022 to Dec. 2023 .

Guizhounli Pharmaceutical Co's Accounts Receivable for the quarter that ended in Jun. 2024 was ¥596 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Guizhounli Pharmaceutical Co's Days Sales Outstanding for the three months ended in Jun. 2024 was 109.12.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Guizhounli Pharmaceutical Co's liquidation value for the three months ended in Jun. 2024 was ¥-52 Mil.


Guizhounli Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Guizhounli Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhounli Pharmaceutical Co Change In Receivables Chart

Guizhounli Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.23 -33.95 -83.04 -79.56 -124.07

Guizhounli Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Guizhounli Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guizhounli Pharmaceutical Co  (SHSE:603439) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Guizhounli Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=595.778/498.202*91
=109.12

2. In Ben Graham's calculation of liquidation value, Guizhounli Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Guizhounli Pharmaceutical Co's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=577.226-1220.514+0.75 * 595.778+0.5 * 288.552
=-52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guizhounli Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Guizhounli Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Guizhounli Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
Executives
Zhang Hong Yu Directors, senior managers
Wang Yi senior management
Zhang Qian Fan Directors, senior managers
Sheng Yong Jian Director

Guizhounli Pharmaceutical Co Headlines

No Headlines